Exact Sciences saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 65 to 75.
How To Invest In Stocks In Both Bull And Bear Markets
This unique rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the best stocks typically have an RS Rating of over 80 in the early stages of their moves. See if Exact Sciences can continue to rebound and hit that benchmark.
Exact Sciences is working on a double bottom with a 72.83 entry. See if it can clear the breakout price in volume at least 40% above average.
The company showed 0% EPS growth last quarter. Sales increased 11%.
The company earns the No. 36 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
